GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints

Alector and GSK Discontinue Phase 2 Alzheimer's Trial for Nivisnebart

Alector and GSK have discontinued their Phase 2 PROGRESS-AD trial for nivisnebart in early-stage Alzheimer’s disease due to a lack of significant efficacy. An independent data board found the study futile, marking Alector's third clinical setback in under two years. This follows the failures of latozinemab in frontotemporal dementia and AL002 in Alzheimer's, leading to significant downsizing. Despite these setbacks, analysts express optimism about Alector's new Alector Brain Carrier (ABC) platform for future neurodegenerative disease assets.

• The Phase 2 PROGRESS-AD trial, evaluating nivisnebart for early-stage Alzheimer’s disease, was halted after an independent data board determined the investigational drug was unlikely to significantly slow disease progression versus placebo. GSK and Alector did not provide specific data but plan to share findings at a future scientific conference.
• This failure is Alector's third clinical setback in less than two years. Previously, the monoclonal antibody latozinemab failed its Phase 3 INFRONT-3 trial for frontotemporal dementia in October 2025, missing primary and key secondary endpoints. Additionally, Alector's investigational antibody AL002, developed with AbbVie, failed a Phase 2 Alzheimer’s trial in November 2024.
• The string of clinical failures has led to significant corporate downsizing at Alector, including a 49% reduction in staff (approximately 116 employees) after the latozinemab miss, and earlier layoffs of 17% and 13% of staff following the AL002 stumble. The initial collaboration with GSK in July 2021 involved a $700 million upfront payment and up to $1.5 billion in milestone payments, much of which will now remain unpaid. Despite these challenges, analysts remain optimistic about Alector's new Alector Brain Carrier (ABC) platform, which aims to improve blood-brain barrier penetration for future candidates.

Nivisnebart's Discontinuation in Early-Stage Alzheimer's

The A4 Study (Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease) represents one of the most comprehensive recent investigations into early-stage Alzheimer's intervention. This multicenter randomized clinical trial evaluated solanezumab, an anti-amyloid antibody, in 812 cognitively unimpaired, amyloid-positive adults aged 65-85 years across sites in the United States, Canada, Australia, and Japan over 240 weeks. The study demonstrated minimal efficacy, with each 10-centiloid reduction in amyloid associated with only a 0.026 higher CDR-SB score (95% CI: -0.013, 0.065), and amyloid reduction mediated merely 14.6% of solanezumab's cognitive effects. These near-zero effect estimates suggest minimal impact of limited amyloid reduction in populations with little disease progression.

Recent Phase III trials of donanemab have shown more promising but clinically limited results in amyloid-positive early Alzheimer's disease patients. The monoclonal antibody targeting amyloid-β plaques demonstrated statistically significant cognitive benefits with an iADRS improvement of +2.93 points (95% CI: 1.52-4.33; P < 0.0001) and functional benefits with CDR-SB reduction of -0.66 points (95% CI: -0.90 to -0.42; P < 0.00001). Enhanced benefits were observed in patients with low to medium tau burden (iADRS +3.80; 95% CI: 2.10-5.50), and the treatment achieved dramatic amyloid clearance with 76.4% of patients reaching amyloid-negative status. However, these improvements did not approach minimal clinically important differences, raising questions about clinical meaningfulness.

Safety profiles across these anti-amyloid therapies reveal concerning patterns, particularly with donanemab showing significantly elevated risks of amyloid-related imaging abnormalities with edema (ARIA-E; RR = 12.90; 95% CI: 8.15-20.43; P < 0.00001) and hemorrhage (ARIA-H; RR = 2.86; 95% CI: 1.61-5.06; P = 0.0003). Treatment discontinuation rates were substantially higher (RR = 3.26; 95% CI: 2.38-4.47; P < 0.00001), though all-cause mortality showed no significant difference. Similarly, lecanemab, while achieving regulatory approval in the EU and demonstrating statistically significant cognitive and functional outcomes, requires stringent safety monitoring for ARIA and faces accessibility challenges due to high costs and limited clinical benefits.

Persistent Hurdles in Alzheimer's Disease Drug Development

Alzheimer's disease drug development continues to face fundamental obstacles that have persisted despite decades of research and substantial investment. Currently approved therapies remain largely symptomatic, failing to halt or reverse neurodegeneration and offering only modest improvements in cognition and global functioning. The absence of disease-modifying treatments represents the most critical unmet need in this therapeutic area.

• Limited therapeutic efficacy: Current treatments provide only symptomatic relief without halting disease progression, with most clinical trials failing to demonstrate significant effects on slowing or halting cognitive decline

• Narrow mechanistic targeting: Existing approaches have focused primarily on acetylcholine and glutamate pathways, providing limited benefits while failing to address the complex molecular mechanisms underlying Alzheimer's disease development

• Drug delivery barriers: Overcoming delivery obstacles to the central nervous system, particularly the blood-brain barrier, remains a central challenge for therapeutic compounds including β-alanine analogues and other potential treatments

• Clinical trial methodology issues: Recruitment difficulties, retention problems, site-to-site variability, and allocation bias from individual variation in cognitive decline speed directly impact trial outcomes and treatment effect estimation

• Translational complexity: Emerging therapies face multiple hurdles including immunogenicity concerns, long-term genomic stability questions, ethical considerations, and evolving regulatory frameworks

• Patient adherence challenges: Oral administration drawbacks and complex treatment regimens requiring imaging studies, cognitive testing, and lumbar punctures negatively impact medication adherence and therapeutic efficacy

• Scientific fragmentation: Despite approximately 1,200 annual publications, the field has failed to provide a unified understanding of disease causes, progression, and optimal intervention strategies

Alector's Pivot to Novel Targets and the ABC Platform

Recent research has identified several promising novel therapeutic targets for Alzheimer's disease that extend beyond traditional amyloid and tau pathways. These emerging targets focus on aging mechanisms, metal ion dysregulation, and neuroimmune signaling. The following targets represent innovative approaches currently being explored in preclinical and early clinical development.

• SIRT1 (Sirtuin 1) - A NAD-dependent class III histone deacetylase that serves as a molecular target capable of reversing or attenuating several hallmarks of aging, particularly within the central nervous system, with activators showing dual senomorphic and senolytic actions

• SIRT1 regulatory mechanisms - This target plays crucial roles in chromatin remodeling, oxidative stress responses, mitochondrial biogenesis, and neuroplasticity, with region-specific functions in the hippocampus and hypothalamus essential for memory, energy homeostasis, and stress resilience

• Age-related SIRT1 pathway restoration - SIRT1 depletion during aging contributes to synaptic dysfunction, impaired cognitive function, and susceptibility to neurodegenerative diseases, with therapeutic potential supported by preclinical and early clinical studies for preventing or delaying brain aging

• Metal ion chelation via multifunctional agents - Novel compounds capable of addressing metal ion-induced abnormalities, oxidative stress, and toxic beta amyloid aggregates simultaneously, representing a multi-targeted therapeutic approach

• BDP-CLQ (BODIPY-Clioquinol hybrid) - The first boron dipyrromethene-based bifunctional copper chelator with clioquinol, demonstrating effective copper chelation (pK = 16.6 ± 0.3), potent Aβ aggregation inhibition, reduction in Aβ-induced neuronal cell stiffness, and antioxidant activity

• Theranostic probe development - BDP-CLQ represents a breakthrough as the first compound capable of both optical detection of Aβ fibrils (3-fold and 5-fold fluorescence increase at 650 nm and 565 nm) and therapeutic copper chelation, enabling combined diagnostic and therapeutic applications

TREM2's Clinical Setback: Rethinking Neuroinflammation in AD

The recent discontinuation of a Phase 2 trial for nivisnebart marks another significant setback in the challenging landscape of Alzheimer's disease (AD) drug development, particularly for Alector. This follows previous failures, notably that of AL002, a TREM2 agonistic antibody, which despite extensive preclinical promise, failed to meet its primary endpoint in a Phase 2 trial for early AD. The TREM2 pathway, expressed on microglia, is crucial for regulating immune responses, phagocytosis of amyloid beta, and inflammation. Studies indicated AL002 achieved central nervous system target engagement, reducing soluble TREM2 and increasing biomarkers of TREM2 signaling in cerebrospinal fluid. However, these pharmacodynamic responses did not translate into significant clinical benefits as measured by the Clinical Dementia Rating-Sum of Boxes score.

This outcome raises critical questions for the field:

• Is TREM2 agonism alone sufficient to meaningfully alter AD progression, or is a more nuanced approach required?

• Are current treatment timings, dosages, or patient selection criteria optimized for such complex immunomodulatory targets?

Furthermore, the frequent occurrence of amyloid-related imaging abnormalities (ARIA) with AL002 highlights potential safety considerations that could impact the broader applicability of TREM2-targeted therapies. While Alector faces significant strategic implications, including a likely pivot towards its Alector Brain Carrier (ABC) platform, the broader takeaway for AD research is the reinforced need for combination therapies or highly stratified patient populations. The intricate interplay of immune pathways, amyloid aggregation, and tau hyperphosphorylation suggests that single-target interventions may struggle against the multifactorial nature of AD. Future success may hinge on refining our understanding of disease heterogeneity and developing strategies that address multiple pathological hallmarks simultaneously.